1 Small TSX Cannabis Player to Consider Today

In the cannabis space, The Valens Company (TSX:VLNS) remains a top pick of mine for high-growth investors today.

| More on:
edit Jars of marijuana

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The cannabis sector is notoriously speculative right now. There’s a merger on the books to create the world’s largest cannabis company. And this behemoth already has competition in this regard.

As speculation around U.S. legalization picks up, more attention is going south of the border. However, there are a few niche Canadian cannabis options that look intriguing right now.

Let’s dive into one such opportunity I think could be a unique speculative buy for cannabis investors.

Impressive financials for this small Canadian cannabis player

The Valens Company (TSX:VLNS) is a relatively smaller player in the Canadian cannabis industry. How small? Well, the company has got a market capitalization of $440 million at the time of writing.

Indeed, that’s not microscopic by most standards. But compared to the company’s larger peers, Valens appears to be overlooked by many investors.

The company reported some rather impressive financial results during its most recent quarterly earnings release. Valens reported massive quarter-over-quarter revenue growth of 25%. The company produced $20 million in revenue in the first quarter alone. This growth was driven in product sales of 1.4 million units (23% increase) and a rise in provincial orders of 8%, despite falling sales in the first two months of the quarter.

Indeed. cannabis sales are heating up in Canada, and Valens appears to be well positioned to take advantage of this trend.

Additionally, Valens’s margins look pretty decent as well. The company’s EBITDA margin improved this past quarter, boosting Valens’s balance sheet further. An equity offering on Jan. 29 provided the company with an additional $40 million in growth capital. There’s speculation building that Valens could use this capital to expand into the United States. That said, this is just speculation at this time.

I think Valens is in an intriguing position as a high-growth option in the Canadian cannabis space. For investors looking for cannabis companies with the numbers to support their sky-high valuations, this is one to look at.

Strong Cannabis 2.0 potential spurring interest in Valens stock

Valens is also keen on exploring alternative cannabis products to diversify its product portfolio. These Cannabis 2.0 products span a range of value-added products, including vapes and edibles, and are extremely popular among consumers. Expectations are that Valens’s move into this space will provide further revenue growth acceleration over the long term. Additionally, these higher-margin products have great potential to boost Valens’s profitability over the long term.

The company recently launched three additional vape cartridge products in response to the staggering popularity of its first flavour in association with Verse Cannabis. These products have done quite well and are contributing to the company’s impressive growth trajectory today.

Additionally, Valens introduced other innovative 2.0 products, including high-potency CBD-dominant oil. The coming quarters will see even more product launches like menthol rubs, bath bombs, premium oils, and water drops.

With an impressive catalog of pioneering product launches, speculative investors may want to consider this stock. Valens is a unique high-growth company, focused on the correct (profitable) growth segments that I think matter.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Chris MacDonald has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Valens GroWorks.

More on Cannabis Stocks

Cannabis Stocks

TFSA Investors: 2 U.S. Stocks I’m Never Selling

Canadians looking to diversify their portfolios and gain exposure to U.S. stocks can purchase shares of high-growth companies such as…

Read more »

A cannabis plant grows.
Cannabis Stocks

Aurora Cannabis (TSX:ACB) Keeps Burning Cash as Revenue Falls

Aurora Cannabis (TSX:ACB)(NASDAQ:ACB) is still losing money. Its revenue is declining, too.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Canopy Growth Stock Climbed as Much as 20% on Monday

A glimmer of hope from the U.S. Congress may lead to renewed interest in marijuana investing.

Read more »

TSX Today
Cannabis Stocks

TSX Today: What to Watch for in Stocks on Friday, July 15

A continued selloff in metals prices is likely to pressure the commodity-heavy TSX Composite benchmark at the open today.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

With the Cannabis Industry Trading Ultra-Cheap, Organigram Stock Looks Like a Screaming Buy!

After selling off for years, Organigram stock now offers tonnes of value and is easily one of the best cannabis…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »